Tezampanel anhydrous
As of the edition of 20 October 2026, Tezampanel anhydrous is a small molecule: in active development; acts on GRIA1, GRIA2 and GRIA3 and 6 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 2, 0 stopped early
- Disease areas
- Chemically induced; Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| GRIK1 | Glutamate receptor ionotropic, kainate 1 | P39086 |
| GRIA1 | Glutamate receptor 1 | P42261 |
| GRIA2 | Glutamate receptor 2 | P42262 |
| GRIA3 | Glutamate receptor 3 | P42263 |
| GRIA4 | Glutamate receptor 4 | P48058 |
| GRIK2 | Glutamate receptor ionotropic, kainate 2 | Q13002 |
| GRIK3 | Glutamate receptor ionotropic, kainate 3 | Q13003 |
| GRIK4 | Glutamate receptor ionotropic, kainate 4 | Q16099 |
| GRIK5 | Glutamate receptor ionotropic, kainate 5 | Q16478 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| TorreyPines Therapeutics | Lead sponsor of trials | 2006 to now |
| Proniras | Lead sponsor of trials | 2024 to now |